For the quarter ending 2026-03-31, TARA had -$34,920K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -17,782 | -17,307 | -13,258 | -26,874 |
| Stock-based compensation | 1,362 | 1,043 | 1,047 | 1,736 |
| Operating lease right-of-use asset | 283 | 278 | 273 | 530 |
| Depreciation | 90 | 93 | 88 | 181 |
| Realized loss (gain) on redemption of marketable debt securities | - | 9 | - | - |
| Amortization of premium (accretion of discount) on marketable debt securities | -190 | -317 | -396 | -532 |
| Prepaid expenses and other current assets | 261 | 976 | 99 | 1,012 |
| Other assets | 3,030 | -60 | -58 | -204 |
| Accounts payable | 1,089 | -1,562 | -795 | 1,484 |
| Accrued expenses and other current liabilities | -2,602 | 2,044 | 922 | -2,145 |
| Operating lease liabilities | -302 | -297 | -292 | -535 |
| Purchase of property and equipment | - | 24 | 4 | 66 |
| Net cash provided by (used in) operating activities | -21,343 | -16,950 | -12,452 | -26,963 |
| Purchase of marketable debt securities | 43,857 | 62,708 | 24,412 | 117,511 |
| Proceeds from maturity and redemption of marketable debt securities | 29,136 | 35,824 | 17,910 | 11,500 |
| Net cash provided by (used in) investing activities | -14,721 | -26,908 | -6,506 | -106,077 |
| Proceeds from exercise of warrants | - | 1 | - | - |
| Proceeds from exercise of pre-funded warrants | - | - | 0 | 1 |
| Proceeds from december 2025 public offering, net of offering costs of 5,286 | - | 80,964 | - | - |
| Proceeds from exercise of stock options | - | 0 | 13 | 8 |
| Proceeds from exercise of underwriters option in december 2024 public offering, net of offering costs of 214 | - | 0 | 0 | 2,528 |
| Offering costs paid in connection with public offerings | 526 | 0 | 0 | 614 |
| Proceeds from private placement, net of offering costs of 3,034 | - | - | - | 0 |
| Proceeds from exercise of warrants | 1,942 | - | - | - |
| Taxes paid related to net share settlement of restricted stock units | 272 | 0 | 0 | 185 |
| Net cash provided by (used in) financing activities | 1,144 | 80,964 | 13 | 1,738 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -34,920 | 37,106 | -18,945 | -131,302 |
| Cash and cash equivalents and restricted cash - beginning of period | 13,296 | - | 163,543 | - |
| Cash and cash equivalents and restricted cash - end of period | 15,482 | - | 13,296 | - |
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)